Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma

    Cancer Categories
    • Genitourinary (GU)
    Karmanos Trial ID
    • 2018-131
    NCT ID
    • NCT03634540
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase II
    Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
    • Phase II
    Principal Investigator

    Objective:

    Primary
    • To evaluate efficacy of PT2977 in combination with cabozantinib for the treatment of advanced clear cell renal cell carcinoma (ccRCC) as measured by overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
    Secondary
    • To evaluate efficacy of PT2977 in combination with cabozantinib for the treatment of advanced ccRCC measured as follows:
      • Progression-free survival (PFS)
      • Duration of response (DOR)
      • Time to response (TTR)
      • Overall Survival (OS)
    • To evaluate the safety and tolerability of PT2977 in combination with cabozantinib
    • To assess the pharmacokinetic (PK) profiles of PT2977 and cabozantinib
  • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266